Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Pyridostigmine toxicity. Electrophysiological study

K H Park¹, D E Kim, T W Arnold

¹Department of Neurology, University of Alabama at Birmingham.

Electromyography and Clinical Neurophysiology

|September 1, 1993

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies.

ESMO open·2026

Same author

A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21).

ESMO open·2025

Same author

Corrigendum to "A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)": [ESMO Open 9 (2024) 103668].

ESMO open·2025

Same author

Dissecting the Sensitization Profiles in Parvalbumins From 12 Freshwater Fish Species to Improve Diagnosis of Fish Allergy.

Journal of investigational allergology & clinical immunology·2025

Same author

Corrigendum to "Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18": [ESMO Open 8 (2023) 101588].

ESMO open·2024

High doses of pyridostigmine can cause muscle weakness. Nerve conduction studies revealed distinct responses indicating varying levels of pyridostigmine toxicity, which resolved upon dose reduction.

Area of Science:

Neurology
Clinical Electrophysiology

Background:

Pyridostigmine is commonly used to treat neuromuscular disorders.
High dosages may lead to adverse effects, including muscle weakness.

Observation:

A 54-year-old patient experienced proximal weakness while on 3600 mg of pyridostigmine daily.
Nerve conduction studies (RNS) demonstrated three distinct response patterns.
These patterns correlated with varying degrees of pyridostigmine toxicity and were reproducible in vitro.

Findings:

One observed RNS pattern, characterized by repetitive discharge and a "dip phenomenon" (decrement followed by increment), is typical of anticholinesterase toxicity.
The patient's clinical symptoms and electrophysiological findings improved after reducing the pyridostigmine dosage.

Related Experiment Videos

Implications:

This case highlights the potential for pyridostigmine toxicity at high doses.
Electrophysiological testing, specifically RNS, can effectively diagnose and quantify anticholinesterase-induced neuromuscular dysfunction.
Careful dose titration and monitoring are crucial for patients on pyridostigmine therapy.